PortfoliosLab logoPortfoliosLab logo
NVNO vs. ACXP
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

NVNO vs. ACXP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in enVVeno Medical Corporation (NVNO) and Acurx Pharmaceuticals, Inc. (ACXP). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, NVNO achieves a -5.59% return, which is significantly higher than ACXP's -42.17% return.


NVNO

1D
-0.25%
1M
-4.59%
6M
-11.15%
YTD
-5.59%
1Y
-93.78%
3Y*
-61.19%
5Y*
-45.26%
10Y*
ALL TIME*
-52.17%

ACXP

1D
1.41%
1M
-10.00%
6M
-39.11%
YTD
-42.17%
1Y
-76.55%
3Y*
-66.87%
5Y*
-58.26%
10Y*
ALL TIME*
-57.93%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$106.69K$141.74K$162.46K
$234.78K$235.71K$143.02K

NVNO vs. ACXP - Yearly Performance Comparison


2026 (YTD)20252024202320222021
NVNO
enVVeno Medical Corporation
-5.59%-89.38%-41.25%0.78%-22.61%1.23%
ACXP
Acurx Pharmaceuticals, Inc.
-42.17%-84.71%-78.75%-3.77%-7.90%-27.37%

Correlation

The correlation between NVNO and ACXP is 0.27, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.27

Correlation (3Y)
Balances recent behavior with more history.

0.21

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.15

Correlation (All Time)
Calculated using the full available price history since Jun 25, 2021

0.15

The correlation between NVNO and ACXP shifts across timeframes, from 0.15 (5 years) to 0.27 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

NVNO:

$174.93K

ACXP:

$2.28M

EPS

NVNO:

-$87.31

ACXP:

-$866.03

PB Ratio

NVNO:

0.34

ACXP:

0.00

Total Revenue (TTM)

NVNO:

$0.00

ACXP:

$0.00

Gross Profit (TTM)

NVNO:

-$361.00K

ACXP:

$0.00

EBITDA (TTM)

NVNO:

-$15.56M

ACXP:

-$5.88M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

NVNO vs. ACXP — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

NVNO
NVNO Risk / Return Rank: 88
Overall Rank
NVNO Sharpe Ratio Rank: 99
Sharpe Ratio Rank
NVNO Sortino Ratio Rank: 55
Sortino Ratio Rank
NVNO Omega Ratio Rank: 22
Omega Ratio Rank
NVNO Calmar Ratio Rank: 33
Calmar Ratio Rank
NVNO Martin Ratio Rank: 2020
Martin Ratio Rank

ACXP
ACXP Risk / Return Rank: 1919
Overall Rank
ACXP Sharpe Ratio Rank: 2525
Sharpe Ratio Rank
ACXP Sortino Ratio Rank: 2626
Sortino Ratio Rank
ACXP Omega Ratio Rank: 2727
Omega Ratio Rank
ACXP Calmar Ratio Rank: 66
Calmar Ratio Rank
ACXP Martin Ratio Rank: 1212
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

NVNO vs. ACXP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for enVVeno Medical Corporation (NVNO) and Acurx Pharmaceuticals, Inc. (ACXP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


NVNOACXPDifference
Sharpe ratioReturn per unit of total volatility

-0.38

Sortino ratioReturn per unit of downside risk

-1.40

Omega ratioGain probability vs. loss probability

0.72

0.97

-0.25

Calmar ratioReturn relative to maximum drawdown

-0.98

-0.94

-0.05

Martin ratioReturn relative to average drawdown

-1.05

-1.29

+0.24

NVNO vs. ACXP - Sharpe Ratio Comparison

The current NVNO Sharpe Ratio is -0.80, which is lower than the ACXP Sharpe Ratio of -0.42. The chart below compares the historical Sharpe Ratios of NVNO and ACXP, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

NVNO vs. ACXP - Drawdown Comparison

The maximum NVNO drawdown since its inception was -99.81%, roughly equal to the maximum ACXP drawdown of -99.14%. Use the drawdown chart below to compare losses from any high point for NVNO and ACXP.


Loading charts...

Drawdown Indicators


NVNOACXPDifference

Max Drawdown

Largest peak-to-trough decline

-99.81%

-99.14%

-0.67%

Max Drawdown (1Y)

Largest decline over 1 year

-95.04%

-83.33%

-11.71%

Max Drawdown (3Y)

Largest decline over 3 years

-96.27%

-98.83%

+2.56%

Max Drawdown (5Y)

Largest decline over 5 years

-97.66%

-98.84%

+1.18%

Current Drawdown

Current decline from peak

-99.77%

-99.09%

-0.68%

Average Drawdown

Average peak-to-trough decline

-90.11%

-70.16%

-19.95%

Ulcer Index

Depth and duration of drawdowns from previous peaks

88.64%

60.56%

+28.08%

Volatility

NVNO vs. ACXP - Volatility Comparison

The current volatility for enVVeno Medical Corporation (NVNO) is 13.76%, while Acurx Pharmaceuticals, Inc. (ACXP) has a volatility of 20.58%. This indicates that NVNO experiences smaller price fluctuations and is considered to be less risky than ACXP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


NVNOACXPDifference

Volatility (1M)

Calculated over the trailing 1-month period

13.76%

20.58%

-6.82%

Volatility (6M)

Calculated over the trailing 6-month period

56.04%

120.16%

-64.12%

Volatility (1Y)

Calculated over the trailing 1-year period

116.84%

185.91%

-69.07%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

81.71%

139.94%

-58.23%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

93.20%

139.84%

-46.64%

Dividends

NVNO vs. ACXP - Dividend Comparison

Neither NVNO nor ACXP has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

NVNO vs. ACXP - Financials Comparison

This section allows you to compare key financial metrics between enVVeno Medical Corporation and Acurx Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

Frequently Asked Questions


NVNO and ACXP have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ACXP has higher volatility (20.58%) compared to NVNO (13.76%). In terms of maximum drawdown, NVNO dropped -99.81% vs ACXP's -99.14%.

ACXP currently has the higher Sharpe Ratio (-0.42 vs -0.80), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for NVNO and ACXP

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer